Pay in 4 interest-free payments of $5.91 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Fig.2 Pleiotropic effects of GLP1-RA leading to improvement MASLD/MASH [2] GLP-1RA in MASH Treatment: Clinical Progress Several GLP-1RAs and related agents are currently in various phases of clinical development for MASH treatment [4]
If you have specific concerns about how your diet interacts with the GLP-1 youre on, consult your health provider
PMCID: PMC6102891
PMCID: PMC1204764.
Safety Profile: What We Learned About Side Effects Common Adverse Events The TRIUMPH-4 trial confirmed that retatrutide's side effect profile aligns with other incretin-based therapies, with gastrointestinal symptoms being the most common: Incidence of GI Side Effects (12mg dose): Nausea: 43% (vs 11% placebo) Diarrhea: 33% (vs 13% placebo) Vomiting: 21% (vs 0% placebo) Constipation: Elevated vs placebo Decreased appetite: Common Most gastrointestinal side effects were mild to moderate in severity and occurred primarily during the dose escalation phase
US$ 25.54
US$ 29.60
US$ 24.54
US$ 25.17
US$ 27.38
